Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 6, Issue 4, Pages 364-368Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2006.02.004
Keywords
-
Categories
Ask authors/readers for more resources
Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been extensively investigated in the pre-clinical setting as a strategy for chemo- or radio-potentiation. Recent evidence has suggested that PARP inhibitors might be active as single agents in certain rare inherited cancers that carry DNA repair defects. As a result, potent PARP-1 inhibitors have in the past three years entered early clinical trials in cancer patients, and the final results of these trials are eagerly awaited.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available